Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients

Y. W. Chen; S. C. Tang; L. K. Tsai; S. J. Yeh; H. Y. Chiou; P. K. Yip; J. S. Jeng

doi:10.1111/j.1468-1331.2012.03847.x

Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients

Y. W. Chen, S. C. Tang, L. K. Tsai, S. J. Yeh, H. Y. Chiou, P. K. Yip, J. S. Jeng

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P

Original language	English
Pages (from-to)	1128-1134
Number of pages	7
Journal	European Journal of Neurology
Volume	20
Issue number	8
DOIs	https://doi.org/10.1111/j.1468-1331.2012.03847.x
Publication status	Published - Aug 2013

Keywords

Anticoagulants
Antiplatelet
Cerebral hemorrhage
Warfarin

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.1111/j.1468-1331.2012.03847.x

Fingerprint Dive into the research topics of 'Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients'. Together they form a unique fingerprint.

Cite this

@article{b3b65e596ae64f71b25418919cf7ee10,

title = "Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients",

abstract = "Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P ",

keywords = "Anticoagulants, Antiplatelet, Cerebral hemorrhage, Warfarin",

author = "Chen, {Y. W.} and Tang, {S. C.} and Tsai, {L. K.} and Yeh, {S. J.} and Chiou, {H. Y.} and Yip, {P. K.} and Jeng, {J. S.}",

year = "2013",

month = aug,

doi = "10.1111/j.1468-1331.2012.03847.x",

language = "English",

volume = "20",

pages = "1128--1134",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients

AU - Chen, Y. W.

AU - Tang, S. C.

AU - Tsai, L. K.

AU - Yeh, S. J.

AU - Chiou, H. Y.

AU - Yip, P. K.

AU - Jeng, J. S.

PY - 2013/8

Y1 - 2013/8

N2 - Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P

AB - Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P

KW - Anticoagulants

KW - Antiplatelet

KW - Cerebral hemorrhage

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84880109055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880109055&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2012.03847.x

DO - 10.1111/j.1468-1331.2012.03847.x

M3 - Article

C2 - 22897602

AN - SCOPUS:84880109055

VL - 20

SP - 1128

EP - 1134

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 8

ER -